Biosimilars, PCSK9s, Value-Based Care Among Hot-Button Topics Tracked in New AIS Book

Share Article

New from Atlantic Information Services, Specialty Pharmacy Trends and Strategies: 2016-2017 Edition is a convenient source for details on the latest management strategies and tactics.

Recently published by Atlantic Information Services, Inc. (AIS), Specialty Pharmacy Trends and Strategies: 2016-2017 Edition, tracks hot-button issues in the specialty pharmacy industry that will affect PBMs and insurers in 2016 and beyond, including the rise of biosimilars, PCSK9s and value-based initiatives:

  • According to reporting in Specialty Pharmacy Trends and Strategies, Express Scripts, Inc. has estimated that Zarxio — the first biosimilar approved by the Food and Drug Administration — has the potential to save U.S. patients and payers $5.7 billion between 2014 and 2024 and additional drugs in the biosimilar pipeline could save an estimated $250 billion in savings over the next 10 years. But a lawsuit (Amgen Inc., Amgen Manufacturing Limited v. Sandoz Inc., No. 15-1499) raised several questions, including patent issues based on the language of the Biologics Price Competition and Innovation Act of the Affordable Care Act, and delayed Zarxio’s launch. The book tracks the lawsuit and its implications, as well as the biosimilar space as whole, and provides historical background and future insight.
  • Specialty Pharmacy Trends and Strategies also follows the impact of cholesterol-lowering PCSK9 inhibitors hitting the market, boasting costs $5,000 higher than industry insiders expected and causing pharmacy benefit managers to either balk at coverage or negotiate pay-for-performance deals with manufacturers. Cardiologists are excited for their potential, but health plans and PBMs have shown reluctance to fully embrace these super-statins. The book charts the implications for specialty pharmacy spend.
  • One way payers are attempting to control costs of new drug innovations is the use of value-based initiatives, from bundled payments and other strategies in the oncology space to the use of quality-based pharmacy networks to drive better outcomes and thus lower prices. Specialty Pharmacy Trends and Strategies follows pilots and proposals undertaken by insurers, PBMs and the federal government to tie reimbursement and benefit design to more positive results for patients and payers.

For more information on Specialty Pharmacy Trends and Strategies: 2016-2017 Edition, including a full table of contents, visit https://aishealth.com/marketplace/specialty-pharmacy-trends-and-strategies.

About AIS
Atlantic Information Services, Inc. (AIS) is a publishing and information company that has been serving the health care industry for nearly 30 years. It develops highly targeted news, data and strategic information for managers in hospitals and health systems, health insurance companies, medical group practices, purchasers of health insurance, pharmaceutical companies and other health care organizations. AIS products include print and electronic newsletters, databases, websites, looseleafs, strategic reports, directories, webinars, virtual conferences and training programs. Learn more at http://AISHealth.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Susan Namovicz-Peat, Director, Directories and Databases Division
@AISHealth
Follow >
AISHealth
since: 01/2011
Like >
Atlantic Information Services, Inc.

Visit website